Compare Quest Diagnostics Inc (DGX) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Transocean Ltd — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Transocean Ltd trades at $5.57 (market cap $6.02B). The key difference: Quest Diagnostics Inc is far larger — about 4.2× Transocean Ltd's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Transocean Ltd for 18 Days on average.
| DGX | RIG | |
|---|---|---|
Market Cap | $25.06B | $6.02B |
Volume | 927,361 | 19,180,005 |
Sector | Health | Energy |
52-Week High | $247.45 | $7.58 |
52-Week Low | $173.49 | $3.08 |
Typical Hold Time | 56 Days | 18 Days |
Enterprise Value | $30.82B | $10.63B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
RIG trades at $5.39, down 0.19% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025, though revenue remains solid at $3.97 billion. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract wins, while analyst sentiment is divided with a 39% buy rating.
The outlook hinges on successful deleveraging and offshore cycle strength, but high debt and persistent losses pose significant risks. Investment appeal is speculative, dependent on cash flow improvements and debt reduction outweighing current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
